Globally, trastuzumab deruxtecan is authorized in additional than 40 international locations (Representational)

New Delhi:

AstraZeneca Pharma India Ltd on Wednesday stated it has obtained an approval from the Drug Controller General of India (DCGI) for the most cancers drug trastuzumab deruxtecan for remedy of metastatic breast most cancers.

The firm stated it has been granted approval to import and market trastuzumab deruxtecan used within the remedy of choose “HER-2 positive” breast most cancers.

“The India approval is based on a global, head-to-head, randomised, open label, registrational Phase III trial DESTINY Breast 03. Globally, trastuzumab deruxtecan is approved in more than 40 countries, including the US, for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer,” AstraZeneca Pharma India stated in a press release.

HER2 is a type of growth-promoting protein expressed on the floor of a number of tumours, together with breast, gastric, lung and colorectal cancers, and is without doubt one of the biomarkers expressed in breast most cancers tumours, it added.

“India’s approval of trastuzumab deruxtecan marks a significant clinical advancement allowing us to help more patients across the HER2 spectrum,” AstraZeneca India Country President and Managing Director Sanjeev Panchal stated. 

(Except for the headline, this story has not been edited by NDTV workers and is revealed from a syndicated feed.)